Published on
September 30, 2024
- 10:09 GMT
3io Therapeutics Announces the Appointment of Dr. Michael Tusche as Chief Executive Officer
TORONTO, ONTARIO, CANADA, September 30, 2024 /EINPresswire.com/ -- 3io Therapeutics, a preclinical stage biotechnology company developing next generation viral immunotherapies for hard-to-treat cancers, today announced that it has appointed Michael …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
